VIVUS Inc. is a biopharmaceutical company that is currently focused on developing therapies that tackle diseases such as obesity, sleep apnea, diabetes, and male sexual health. One of its key products, Qnexa, has successfully completed Phase 3 clinical trials for obesity treatment and is also in Phase 2 clinical development for sleep apnea and diabetes. The company continues to move forward with its research and development efforts to tackle some of the most pressing health issues affecting populations today.